Madrigal Pharmaceuticals

$121.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.87 (-1.52%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell MDGL and other stocks, options, and ETFs commission-free!

About MDGL

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA. The listed name for MDGL is Madrigal Pharmaceuticals, Inc. Common Stock.

CEO
Paul A. Friedman
Employees
29
Headquarters
West Conshohocken, Pennsylvania
Founded
2011
Market Cap
1.83B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
140.68K
High Today
$124.65
Low Today
$119.67
Open Price
$123.00
Volume
104.89K
52 Week High
$137.28
52 Week Low
$56.82

MDGL Earnings

-$3.82
-$2.55
-$1.27
-$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
-$3.82 per share

You May Also Like

OSIS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure